SCHEMBL3216775

SCHEMBL3216775

O=S(=O)(c1ccccc1C(F)(F)F)N(Br)CC1CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
RAB9A P51151 1/20 0.42
SLC6A2 P23975 5/20 0.41
SLC6A4 P31645 5/20 0.41
NPY1R P25929 2/20 0.41
NPY5R Q15761 2/20 0.41
HSD11B1 P28845 2/20 0.40
DPP4 P27487 1/20 0.40
DPP8 Q6V1X1 1/20 0.40
DPP9 Q86TI2 1/20 0.40
DPP7 Q9UHL4 1/20 0.40
CNR2 P34972 4/20 0.39
SLC22A12 Q96S37 2/20 0.38
CNR1 P21554 1/20 0.38
RORC P51449 1/20 0.37
HTR1A P08908 1/20 0.36
DRD2 P14416 1/20 0.36
HTR2A P28223 1/20 0.36
HTR7 P34969 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2833939 0.70 RORC (0.45) MEN1KMT2ARAB9ASLC6A2SLC6A4
SCHEMBL13232688 0.70 RORC (0.45) MEN1KMT2ARAB9ASLC6A2SLC6A4
SCHEMBL27642658 0.70 MEN1 (0.51) MEN1KMT2ARAB9AHSD11B1DPP4
SCHEMBL4282662 0.69 HTR2C (0.48) MEN1KMT2ASLC6A2SLC6A4SLC6A3
SCHEMBL3235852 0.69 ATM (0.48) MEN1KMT2ARAB9ASLC6A2SLC6A4
Hydrochloric Acid SCHEMBL28351640 0.68 MEN1 (0.50) MEN1KMT2ARAB9AHSD11B1DPP4
SCHEMBL8770173 0.67 HSD11B1 (0.49) MEN1KMT2ARAB9AHSD11B1SLC22A12
SCHEMBL27993985 0.67 MEN1 (0.56) MEN1KMT2AHSD11B1SLC22A12CYP3A4
SCHEMBL17300878 0.67 NPY5R (0.43) MEN1KMT2ASLC6A2SLC6A4NPY5R
SCHEMBL29874131 0.66 MEN1 (0.60) MEN1KMT2AHSD11B1SLC22A12CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9422235-B2 Sulfonamide derivatives with therapeutic indications PHARMOS CORPORATION (US) 2016-08-23 US disclosed
US-20100056528-A1 SULFONAMIDE DERIVATIVES WITH THERAPEUTIC INDICATIONS PHARMOS CORPORATION 2010-03-04 US disclosed
EP-2139852-A1 SULFONAMIDE DERIVATIVES WITH THERAPEUTIC INDICATIONS Pharmos Corporation (US) 2010-01-06 EP disclosed
WO-2008075353-A1 SULFONAMIDE DERIVATIVES WITH THERAPEUTIC INDICATIONS PHARMOS CORPORATION (US) 2008-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100056528-A1 SULFONAMIDE DERIVATIVES WITH THERAPEUTIC INDICATIONS SULT2A1, STS, SULT1A1 MEN1 3529/4885KMT2A 2371/4885RAB9A 3332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.